Get the Stockscreener App
2.64
5.38%
-0.15
Pre-market:
2.64
Erasca Inc stock is traded at $2.64, with a volume of 726.36K.
It is down -5.38% in the last 24 hours and down -9.28% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$2.79
Open:
$2.77
24h Volume:
726.36K
Relative Volume:
0.39
Market Cap:
$746.40M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.4831
EPS:
-1.78
Net Cash Flow:
$-122.99M
1W Performance:
-7.37%
1M Performance:
-9.28%
6M Performance:
+17.86%
1Y Performance:
+17.33%
1-Day Range:
$2.60
$2.82
1-Week Range:
$2.60
$2.97
52-Week Range:
$1.51
$3.45
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Compare ERAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ERAS | 2.64 | 746.40M | 0 | -125.04M | -122.99M | -1.78 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Erasca Inc Stock (ERAS) Latest News
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Jefferies Financial Group Begins Coverage on Erasca (NASDAQ:ERAS) - Defense World
Erasca (NASDAQ:ERAS) Shares Gap UpTime to Buy? - MarketBeat
Erasca, Inc. (NASDAQ:ERAS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Erasca (NASDAQ:ERAS) Now Covered by Jefferies Financial Group - MarketBeat
Erasca initiated with a Buy at Jefferies - TipRanks
Jefferies bullish on Erasca stock as promising RAS-targeted therapies drive upside By Investing.com - Investing.com South Africa
Jefferies bullish on Erasca stock as promising RAS-targeted therapies drive upside - Investing.com Australia
Jefferies Initiates Coverage of Erasca (ERAS) with Buy Recommendation - MSN
FY2024 Earnings Forecast for Erasca Issued By HC Wainwright - MarketBeat
What is HC Wainwright’s Estimate for Erasca FY2024 Earnings? - Defense World
Erasca (NASDAQ:ERAS) Earns “Buy” Rating from HC Wainwright - Defense World
Significant Stake Increase by T. Rowe Price in Erasca Inc - GuruFocus.com
Creative Planning Increases Stake in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Erasca, Inc. Reports Strong Progress in Oncology Pipeline - TipRanks
Erasca's (ERAS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Erasca Reports Third Quarter 2024 Business Updates and Financial Results - The Manila Times
Erasca Reports Strong Phase 1b Data, $463M Cash Position Extends Runway to 2027 | ERAS Stock News - StockTitan
Erasca to Present at Upcoming Investor Conferences - ForexTV.com
Erasca (ERAS) to Present at Three Major Healthcare Investor Conferences | ERAS Stock News - StockTitan
Erasca Insiders Added US$1.95m Of Stock To Their Holdings - Yahoo Finance
Erasca (NASDAQ:ERAS) Shares Up 3.8%Should You Buy? - MarketBeat
The Goldman Sachs Group Raises Erasca (NASDAQ:ERAS) Price Target to $3.50 - Defense World
Erasca (NASDAQ:ERAS) Trading Down 3.4%What's Next? - MarketBeat
Erasca Inc (NASDAQ: ERAS) Stock: Bulls Should Watch This - Stocks Register
Erasca stock gains momentum as Goldman sees potential in melanoma treatment - Investing.com Canada
HC Wainwright Reaffirms Buy Rating for Erasca (NASDAQ:ERAS) - MarketBeat
Erasca reports progress in melanoma treatment trials - Investing.com India
Erasca reports progress in melanoma treatment trials By Investing.com - Investing.com UK
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise - The Manila Times
Erasca, Inc. (NASDAQ:ERAS) Holdings Lowered by Exchange Traded Concepts LLC - Defense World
The Manufacturers Life Insurance Company Increases Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Stock Performance Spotlight: Erasca Inc (ERAS) Ends the Day at 2.81, Up by 2.18 - The Dwinnex
A look into Erasca Inc (ERAS)’s deeper side - SETE News
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth - Simply Wall St
Do investors need to be concerned about Erasca Inc (ERAS)? - US Post News
Erasca Inc [ERAS] Investment Guide: What You Need to Know - Knox Daily
Renaissance Technologies LLC Invests $195,000 in SkyWater Technology, Inc. (NASDAQ:SKYT) - Defense World
Erasca Inc [ERAS] Shares Rise 3.17 % on Wednesday - Knox Daily
A company insider recently bought 10,000 shares of Lumen Technologies Inc [LUMN]. Should You Buy? - Knox Daily
Insider Selling: Caisley Charles A., Evergy Inc [EVRG] SVP – PA & CHIEF CO divested 9,236 shares - Knox Daily
Chairman, President and CEO Simonelli Lorenzo sold 114,286 shares of Baker Hughes Co [BKR] - Knox Daily
Unitedhealth Group Inc [UNH] stock for 1,624,734 USD was sold by ROOS THOMAS E - Knox Daily
Ocean Power Technologies [OPTT] Stock bought by Insider N/A for $N/A - Knox Daily
Myc Proto Oncogene Protein Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, and Companies by DelveInsight | Biogenera SpA, Ceptur Therapeutics Inc, Cothera Bioscience, more - The Globe and Mail
Russell 1000 Value (TXM25) Quote - The Globe and Mail
A year in review: Erasca Inc (ERAS)’s performance in the last year - US Post News
Ratios Revealed: Decoding Erasca Inc (ERAS)’s Financial Health - The Dwinnex
American Century Companies Inc. Raises Stake in Seritage Growth Properties (NYSE:SRG) - Defense World
Chevron Co. (NYSE:CVX) Shares Acquired by Deane Retirement Strategies Inc. - Defense World
ERAS Stock Sees Decline of Approximately -8.03% in Last Five Days - Knox Daily
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):